Pan et al. demonstrated that in pediatric B-cell acute lymphoblastic leukemia (B-ALL), sequential infusion of two different CARs targeting CD19 followed by one targeting CD22 could be a viable strategy to increase the efficacy and safety of CAR-T cell therapy [285]. This evidence concerns the gene CD22 and B-cell acute lymphoblastic leukemia.